Cicely Kerr1, Emily J Lloyd2, Charlotte E Kosmas1, Helen T Smith3, James A Cooper3, Karissa Johnston4, Emma McIntosh5, Andrew J Lloyd6. 1. ICON Patient Reported Outcomes, Oxford, UK. 2. ViiV Healthcare, Brentford, UK. 3. GlaxoSmithKline, Brentford, UK. 4. ICON Epidemiology, Vancouver, Canada. 5. Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK. 6. Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford, UK. Andrew@bladonassoc.com.
Abstract
PURPOSE: Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP). METHODS: PwP across UK, France, Spain and Italy completed an online survey to explore: the impact of 'off time' on (1) health-related quality of life (HRQL) and (2) on functioning and ability to undertake usual activities; (3) the value of 'off time' relative to other factors associated with Parkinson's through a stated preference discrete choice experiment (SPDCE). RESULTS: In total, 305 PwP completed the online survey. Overall mean HRQL (utility) score was significantly lower for 'off time' (0.37) than for 'on time' (0.60). All attributes within the SPDCE were significant predictors of treatment choice, although increased duration of 'on time' (per hour per day: odds ratio (OR) = 1.40) and predictability of 'off time' to within 30 min (OR = 1.42) were valued most highly. CONCLUSIONS: 'On time' and predictability of 'off time' are highly valued by PwP. Due to substantial diurnal variation of Parkinson's symptoms, standard patient-reported outcome (PRO) assessments may not adequately capture the impact of 'off time' on HRQL and participation in daily activities.
PURPOSE: Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP). METHODS: PwP across UK, France, Spain and Italy completed an online survey to explore: the impact of 'off time' on (1) health-related quality of life (HRQL) and (2) on functioning and ability to undertake usual activities; (3) the value of 'off time' relative to other factors associated with Parkinson's through a stated preference discrete choice experiment (SPDCE). RESULTS: In total, 305 PwP completed the online survey. Overall mean HRQL (utility) score was significantly lower for 'off time' (0.37) than for 'on time' (0.60). All attributes within the SPDCE were significant predictors of treatment choice, although increased duration of 'on time' (per hour per day: odds ratio (OR) = 1.40) and predictability of 'off time' to within 30 min (OR = 1.42) were valued most highly. CONCLUSIONS: 'On time' and predictability of 'off time' are highly valued by PwP. Due to substantial diurnal variation of Parkinson's symptoms, standard patient-reported outcome (PRO) assessments may not adequately capture the impact of 'off time' on HRQL and participation in daily activities.
Entities:
Keywords:
EQ-5D utility; Health-related quality of life; Off time; Parkinson’s; Stated preference discrete choice experiment
Authors: Juan Carlos Gómez-Esteban; Beatriz Tijero; Johanne Somme; Roberto Ciordia; Koldo Berganzo; Idoia Rouco; Jose Luis Bustos; Maria Antonia Valle; Elena Lezcano; Juan J Zarranz Journal: J Neurol Date: 2010-10-19 Impact factor: 4.849
Authors: Amnon A Berger; Christopher Robinson; Ariel Winnick; Jonathan Izygon; Binil M Jacob; Mackenzie J Noonan; Alan D Kaye; Jessica S Kaye; Adam M Kaye; Elyse M Cornett; Rutvij J Shah; Omar Viswanath; Ivan Urits Journal: Clin Drug Investig Date: 2021-12-21 Impact factor: 2.859
Authors: Amnon A Berger; Ariel Winnick; Jonathan Izygon; Binil M Jacob; Jessica S Kaye; Rachel J Kaye; Elisa E Neuchat; Adam M Kaye; Edward S Alpaugh; Elyse M Cornett; Andrew H Han; Alan D Kaye Journal: Health Psychol Res Date: 2022-06-28
Authors: Louis S Matza; Kristina S Boye; Jessica B Jordan; Kirsi Norrbacka; Raffaella Gentilella; Amara R Tiebout; Chantelle Browne; Marco Orsini Federici; Giovanni Biricolti; Katie D Stewart Journal: Patient Prefer Adherence Date: 2018-06-06 Impact factor: 2.711
Authors: Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri Journal: Transl Neurodegener Date: 2022-10-13 Impact factor: 9.883
Authors: Sneha Mantri; Madeline Lepore; Briana Edison; Margaret Daeschler; Catherine M Kopil; Connie Marras; Lana M Chahine Journal: J Patient Cent Res Rev Date: 2021-07-19